Literature DB >> 27201655

Budget Impact Analysis of Introducing Biosimilar Infliximab for the Treatment of Auto Immune Disorders In Five European Countries.

A Jha1, A Upton2, W Dunlop1.   

Abstract

Year:  2014        PMID： 27201655     DOI： 10.1016/j.jval.2014.08.1655

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  5 in total

Review 1.  Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.

Authors:  Ira Jacobs; Danielle Petersel; Leah Isakov; Sadiq Lula; K Lea Sewell
Journal:  BioDrugs       Date:  2016-12       Impact factor: 5.807

Review 2.  Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.

Authors:  Ira Jacobs; Danielle Petersel; Lesley G Shane; Chee-Keng Ng; Carol Kirchhoff; Gregory Finch; Sadiq Lula
Journal:  BioDrugs       Date:  2016-12       Impact factor: 5.807

3.  Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.

Authors:  Tim A Kanters; Jelena Stevanovic; Isabelle Huys; Arnold G Vulto; Steven Simoens
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

Review 4.  Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.

Authors:  Steven Simoens; Ira Jacobs; Robert Popovian; Leah Isakov; Lesley G Shane
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

5.  Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.

Authors:  Yifei Liu; Min Yang; Vishvas Garg; Eric Q Wu; Jessie Wang; Martha Skup
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.